Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy

• Chemotherapy initiation and subsequent tumor lysis can release immunogenic antigens. • Advanced staged ovarian cancer associated with dermatomyositis. • PARP Inhibitor initiation can worsen paraneoplastic syndromes like dermatomyositis. • Signs and symptoms of dermatomyositis can be confused with...

Descripción completa

Detalles Bibliográficos
Autores principales: Graves, Stephen M., Backes, Floor J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports and Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651899/
https://www.ncbi.nlm.nih.gov/pubmed/34926755
http://dx.doi.org/10.1016/j.gore.2021.100872
_version_ 1784611485295575040
author Graves, Stephen M.
Backes, Floor J.
author_facet Graves, Stephen M.
Backes, Floor J.
author_sort Graves, Stephen M.
collection PubMed
description • Chemotherapy initiation and subsequent tumor lysis can release immunogenic antigens. • Advanced staged ovarian cancer associated with dermatomyositis. • PARP Inhibitor initiation can worsen paraneoplastic syndromes like dermatomyositis. • Signs and symptoms of dermatomyositis can be confused with chemotherapy side-effects.
format Online
Article
Text
id pubmed-8651899
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86518992021-12-17 Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy Graves, Stephen M. Backes, Floor J. Gynecol Oncol Rep Case Reports and Case Series • Chemotherapy initiation and subsequent tumor lysis can release immunogenic antigens. • Advanced staged ovarian cancer associated with dermatomyositis. • PARP Inhibitor initiation can worsen paraneoplastic syndromes like dermatomyositis. • Signs and symptoms of dermatomyositis can be confused with chemotherapy side-effects. Elsevier 2021-10-02 /pmc/articles/PMC8651899/ /pubmed/34926755 http://dx.doi.org/10.1016/j.gore.2021.100872 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Reports and Case Series
Graves, Stephen M.
Backes, Floor J.
Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
title Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
title_full Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
title_fullStr Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
title_full_unstemmed Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
title_short Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
title_sort acute worsening of dermatomyositis after initiation of parp inhibitor therapy in two women with advanced ovarian malignancy
topic Case Reports and Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651899/
https://www.ncbi.nlm.nih.gov/pubmed/34926755
http://dx.doi.org/10.1016/j.gore.2021.100872
work_keys_str_mv AT gravesstephenm acuteworseningofdermatomyositisafterinitiationofparpinhibitortherapyintwowomenwithadvancedovarianmalignancy
AT backesfloorj acuteworseningofdermatomyositisafterinitiationofparpinhibitortherapyintwowomenwithadvancedovarianmalignancy

Ejemplares similares